Cargando…
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%
BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in Caucasians. Surgical approaches are the most widely used and effective treatment strategies for well-defined BCC. However, for patients with low-risk, superficial BCCs (sBCCs), medical therapy may be a treatment option. In this smal...
Autor principal: | Bettencourt, Miriam S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993252/ https://www.ncbi.nlm.nih.gov/pubmed/27574458 http://dx.doi.org/10.2147/CCID.S109531 |
Ejemplares similares
-
Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study
por: Velin, Marine, et al.
Publicado: (2022) -
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015%
por: Jung, Yu Seok, et al.
Publicado: (2016) -
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel
por: Iannazzone, Silvia S., et al.
Publicado: (2018) -
Ingenol mebutate treatment in keloids
por: De Felice, Bruna, et al.
Publicado: (2015) -
Tattoo removal with ingenol mebutate
por: Cozzi, Sarah-Jane, et al.
Publicado: (2017)